A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 1,201,848 shares of CCCC stock, worth $5.26 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,201,848
Previous 278,580 331.42%
Holding current value
$5.26 Million
Previous $1.29 Million 432.25%
% of portfolio
0.02%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.43 - $7.38 $4.09 Million - $6.81 Million
923,268 Added 331.42%
1,201,848 $6.85 Million
Q2 2024

Aug 14, 2024

SELL
$4.05 - $8.1 $2.54 Million - $5.09 Million
-627,892 Reduced 69.27%
278,580 $1.29 Million
Q1 2024

May 15, 2024

SELL
$5.3 - $11.0 $5.59 Million - $11.6 Million
-1,054,887 Reduced 53.78%
906,472 $7.41 Million
Q4 2023

Feb 14, 2024

BUY
$1.18 - $6.03 $2.3 Million - $11.7 Million
1,945,338 Added 12142.43%
1,961,359 $11.1 Million
Q3 2023

Nov 14, 2023

BUY
$1.81 - $3.89 $17,129 - $36,814
9,464 Added 144.33%
16,021 $29,000
Q2 2023

Aug 14, 2023

SELL
$2.75 - $3.77 $47,234 - $64,753
-17,176 Reduced 72.37%
6,557 $18,000
Q1 2023

May 15, 2023

BUY
$3.1 - $9.02 $73,572 - $214,071
23,733 New
23,733 $74,000
Q2 2022

Aug 15, 2022

SELL
$5.06 - $26.46 $2.55 Million - $13.3 Million
-503,888 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$19.99 - $33.23 $10.1 Million - $16.7 Million
503,888 New
503,888 $12.2 Million
Q4 2021

Feb 14, 2022

SELL
$29.39 - $46.86 $5.88 Million - $9.37 Million
-200,000 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$35.91 - $50.5 $1.24 Million - $1.74 Million
34,400 Added 20.77%
200,000 $8.94 Million
Q2 2021

Aug 16, 2021

BUY
$30.39 - $42.18 $5.03 Million - $6.99 Million
165,600 New
165,600 $6.27 Million

Others Institutions Holding CCCC

About C4 Therapeutics, Inc.


  • Ticker CCCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,913,800
  • Market Cap $214M
  • Description
  • C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
More about CCCC
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.